Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akebia TherapeuticsFRA:AX9 +1.60%55 Debt-to-Equity is 1.86 as of Mar. 2026, which is 500% above its 10-year median of 0.31. GuruFocus rates FRA:AX9 with a GF Score™ of 55/100 and a GF Value™ of €1.12 (Fairly Valued). The stock has 5 warning signs investors should review. Among 811 Drug Manufacturers companies, Akebia Therapeutics ranks worse than 94.7% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Akebia Therapeutics's Debt-to-Equity or its related term are showing as below:
FRA:AX9'
s Debt-to-Equity Range Over the Past 10 Years
Min: -5.77 Med: 0.31 Max: 19.08
Current: 1.86
During the past 13 years, the highest Debt-to-Equity Ratio of Akebia Therapeutics was 19.08. The lowest was -5.77. And the median was 0.31.
FRA:AX9's Debt-to-Equity is ranked worse than 94.7% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs FRA:AX9: 1.86
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Akebia Therapeutics Debt-to-Equity Related Terms
Akebia Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AX9 vs TKNO, ORGO, SIGA: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (FRA:AX9) has a Debt-to-Equity of 1.86 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Akebia Therapeutics and its competitors. This is 500% above median its historical median of 0.31. According to the industry distribution chart, Akebia Therapeutics ranks #768 out of 811 companies in the Drug Manufacturers industry, placing it in the top 94.7%.
Is Akebia Therapeutics' Debt-to-Equity too high?
Akebia Therapeutics' current Debt-to-Equity of 1.86 is 500% above median its 10-year median of 0.31. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Akebia Therapeutics' value of 1.86 is 588.9% above this industry median. Based on the distribution chart, Akebia Therapeutics ranks #768 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Akebia Therapeutics has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Debt-to-Equity compare to TKNO and ORGO?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #768 out of 811 companies for Debt-to-Equity. This places Akebia Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Akebia Therapeutics' value of 1.86 is 588.9% above this benchmark. While the company's 10-year median is 0.31 vs. the industry median of 0.27, Akebia Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akebia Therapeutics's current Debt-to-Equity of 1.86 is 588.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Akebia Therapeutics and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current Debt-to-Equity is 1.86, which is 500% above median its own 10-year median of 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (FRA:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.12, compared to a current price of €1.11 — trading 0.9% below its estimated fair value. The current Debt-to-Equity is 1.86, which is 500% above median its 10-year median of 0.31 and 588.9% above the Drug Manufacturers industry median of 0.27. Akebia Therapeutics' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Akebia Therapeutics (FRA:AX9), the current Debt-to-Equity is 1.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (FRA:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of €1.11 is trading 0.9% below its estimated GF Value™ of €1.12.
GuruFocus considers Akebia Therapeutics to be Fairly Valued.
Key valuation signals for FRA:AX9:
Debt-to-Equity: 1.86 (500% above median its 10-year median of 0.31)
GF Value™: €1.12 vs. price of €1.11 (0.9% below fair value)
Industry Position: 588.9% above the Drug Manufacturers median (#768 of 811)
No single metric tells the full story. See the FRA:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
55GF Score
Get the complete analysis for FRA:AX9
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AX9 has been successfully added to your 
